SCHEMBL6136242

SCHEMBL6136242

COc1ccc(N(C)C(=O)NCc2ccc(Cc3c(-c4ccc(O)cc4)ccc4cc(O)ccc34)cc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ESR1 P03372 4/20 0.47
▸ ESR2 Q92731 3/20 0.47
▸ ROCK2 O75116 1/20 0.41
▸ PPIB P23284 1/20 0.41
▸ MAPT P10636 2/20 0.41
▸ TP53 P04637 1/20 0.41
▸ PDK1 Q15118 3/20 0.39
▸ HSP90AA1 P07900 1/20 0.39
▸ PDK2 Q15119 1/20 0.39
▸ PDK3 Q15120 1/20 0.39
▸ PDK4 Q16654 1/20 0.39
▸ CYP1A2 P05177 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ CSF1R P07333 1/20 0.38
▸ NPC1 O15118 2/20 0.36
▸ RAB9A P51151 2/20 0.36
▸ ERCC1 P07992 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6136101 0.93 ESR1 (0.46) ESR1ESR2ROCK2PDK1CYP3A4
SCHEMBL6136296 0.90 ESR1 (0.45) ESR1ESR2ROCK2MAPTTP53
SCHEMBL6136002 0.90 ESR1 (0.43) ESR1ESR2ROCK2MAPTPDK1
SCHEMBL6136079 0.89 ESR1 (0.42) ESR1ESR2PDK1HSP90AA1MEN1
SCHEMBL6136484 0.89 ESR1 (0.44) ESR1ESR2PPIB
SCHEMBL6136157 0.86 ESR1 (0.40) ESR1ESR2ROCK2MAPTPDK1
SCHEMBL6136146 0.84 SMN1; SMN2 (0.52) ESR1ESR2ROCK2POLBCSF1R
SCHEMBL6136160 0.83 ESR1 (0.44) ESR1ESR2PDK1PDK2PDK3
SCHEMBL6136139 0.81 MTOR (0.47) ESR1ESR2ROCK2MAPTCYP2C9
SCHEMBL6136130 0.80 ESR1 (0.41) ESR1ESR2TP53PDK1PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0895989-B1 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity LILLY CO ELI (US) 2005-05-18 — — EP claimed
US-6509356-B1 Estrogen inhibitory activity method for the treatment of breast cancer in a woman comprising administering to a patient a therapeutically effective amount of a compound ELI LILLY AND COMPANY 2003-01-21 — — US claimed
WO-1999007377-A1 1-[4-(SUBSTITUTED ALKOXY)BENZYL]NAPHTHALENE COMPOUNDS HAVING ESTROGEN INHIBITORY ACTIVITY ELI LILLY AND COMPANY (US) 1999-02-18 — — WO claimed
EP-0895989-A1 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity ELI LILLY AND COMPANY (US) 1999-02-10 — — EP claimed
EP-0895989-B1 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity LILLY CO ELI (US) 2005-05-18 — — EP disclosed
US-6509356-B1 Estrogen inhibitory activity method for the treatment of breast cancer in a woman comprising administering to a patient a therapeutically effective amount of a compound ELI LILLY AND COMPANY 2003-01-21 — — US disclosed
WO-1999007377-A1 1-[4-(SUBSTITUTED ALKOXY)BENZYL]NAPHTHALENE COMPOUNDS HAVING ESTROGEN INHIBITORY ACTIVITY ELI LILLY AND COMPANY (US) 1999-02-18 — — WO disclosed
EP-0895989-A1 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity ELI LILLY AND COMPANY (US) 1999-02-10 — — EP disclosed
Send feedback